PDS Biotechnology (PDSB) Stock: Buy, Sell, or Hold?
PDSB - PDS Biotechnology Corporation Common Stock
$1.44
-0.11 (-7.10%)
▼
5d:
+29.73%
30d:
+103.94%
90d:
+101.57%
WAIT
LOW Confidence
Analysis Updated: Oct 30, 2026 12:00 AM ET
Earnings: Nov 12, 2026
10d
Get Alerted When PDSB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PDSB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PDSB shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: PDSB is currently trading at $1.44, which is considered extended relative to its 30-day fair value range of $0.82 to $1.37.
Technical Outlook: Technically, PDSB is in a strong downtrend. Immediate support is located at $0.90, while resistance sits at $1.70. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: PDSB scores 3/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.00 (+247.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PDSB is in a strong downtrend. Immediate support is located at $0.90, while resistance sits at $1.70. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: PDSB scores 3/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.00 (+247.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.82 -
$1.37
Company Quality Score
24/100
(STRONG SELL)
Volume Confirmation
HIGH
Confidence Score
15.8%
All Signals
- BEARISH: Price extended above range (+5.1% above its trading range)
- BEARISH: Weak technical setup (3/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.1%)
- BULLISH: Trading 247.2% below Wall St target ($5.00)
- WARNING: Composite score 24/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.82 -
$1.37
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.90
Resistance Level
$1.70
Current Trend
Strong Downtrend
Technical data as of
Oct 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.17
Wall Street Target
$5.00
(+247.2%)
Share & Embed Analysis
Last updated: November 01, 2026 3:27 AM ET
Data refreshes hourly during market hours. Next update: 4:27 AM
Data refreshes hourly during market hours. Next update: 4:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PDSB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
25 analysts |
$259 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 56 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 43 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$37 | 67 BUY |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 47 HOLD |
